Status:

RECRUITING

ICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock

Lead Sponsor:

Rennes University Hospital

Conditions:

Sepsis

Septic Shock

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Immunonutrition in intensive care has not yet demonstrated a beneficial effect on organ failure, the acquisition of nosocomial infections, or mortality. It did not correct for acquired immunosuppressi...

Detailed Description

Strategy : Enteral administration of citrulline for 5 days versus iso-nitrogenous placebo. Amino acid assay and immunological parameters (monocytic expression of HLA-DR, MDSCs, cytokines / chemokines...

Eligibility Criteria

Inclusion

  • Septic patients in accordance with the definition of sepsis and septic shock published in 2016 (JAMA) and whose use is recommended by the European Society of Intensive Care Medicine;
  • Initial aggression dated less than 4 days before admission to intensive care (selection of "community" patients). The onset of aggression will be defined by the onset of clinical signs of infection;
  • Patients hospitalized for less than 48 hours before admission to intensive care (selection of patients without malnutrition and immunosuppression acquired in hospital) \*;
  • Patients under invasive mechanical ventilation with a foreseeable ventilation duration\> 2 days \*\*;
  • Exclusive enteral nutrition;
  • Affiliation to a social security scheme;
  • Consent signed by the patient, relative or legal representative or inclusion under emergency procedure
  • Non
  • Progressive Sars-CoV2 infection
  • Pregnancy in progress;
  • Morbid obesity (BMI\> 40);
  • State of immunosuppression defined by at least one of these criteria: continuous administration of steroids at any dose for more than one month before hospitalization, steroids at high doses (\> 0.5 mg / kg / day of methylprednisolone or equivalent), radiotherapy or chemotherapy in the previous year, proven humoral or cellular deficiency;
  • Contraindication to enteral nutrition (SRLF 2016 recommendations: "Enteral nutrition should probably not be used upstream of a high flow digestive fistula in cases of intestinal obstruction, ischemia of the small intestine or digestive hemorrhage. active (Strong agreement) ");
  • Participation in intervention research on a drug, or intervention research that could impact the immune system

Exclusion

  • \- Institution of immunosuppressive therapy such as chemotherapy, cyclophosphamide, high dose corticosteroid therapy (\> 0.5 mg / kg / day ; hydrocortisone used in the management of septic shock is not considered an exclusion criterion).

Key Trial Info

Start Date :

May 20 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 20 2026

Estimated Enrollment :

130 Patients enrolled

Trial Details

Trial ID

NCT04513288

Start Date

May 20 2022

End Date

November 20 2026

Last Update

October 8 2024

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Rennes University Hospital - Medical ICU

Rennes, Brittany Region, France, 35033

2

Rennes University Hospital - Surgical ICU

Rennes, Brittany Region, France, 35033

3

Besançon University Hospital

Besançon, France, 25000

4

Le Mans Hospital

Le Mans, France, 72037